EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dual Silencing of Aminoglycoside Biosynthesis for the Discovery of Novel Antimicrobials in Streptomyces

Yuncong Xu, Yali Du, Jiarong Yu, Yinghui Zhao, Zhenlin Li, Jufen Wang, Yijun Chen, Deli Xiao iD, Xuri Wu iD

Microbial Biotechnology · 2026-07 · 19 (7)

DOI: 10.1111/1751-7915.70407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbial Biotechnology, online erschienen am 12.07.2026. Verfasst von Yuncong Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Synthetic Biology, College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province…. Hauptthemen laut MEDLINE: Streptomyces, Aminoglycosides, Gene Silencing, Anti-Bacterial Agents. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Anti-Infective Drug Research and Development Project at China Pharmaceutical University, Key Research and Development Project of Guangdong Province, National College Students Innovation and Entrepreneurship Training Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Streptomyces species are prolific sources of antimicrobials, yet their vast biosynthetic capacity remains underexploited due to the rediscovery of common antibiotics (e.g., ~1% for streptomycin and ~10% for streptothricin). To address this challenge, we developed a dual‐layer biosynthetic blockade system, designated CI‐ARS 3 , which integrates two orthogonal silencing modules: a competitive transcriptional silencer that represses transcription of the native biosynthetic gene cluster (BGC), and an antisense RNA‐based silencer that facilitates the degradation of BGC‐derived mRNAs and/or translational inhibition. Implemented on a single attB site–integrating plasmid (pSET152‐ aafssf ) encoding both modules, CI‐ARS 3 robustly suppresses streptomycin and streptothricin biosynthesis across 54 Streptomyces strains, achieving an inhibition efficiency of over 97% with high specificity for the target compounds under the tested conditions. The removal of these dominant backgrounds led to the discovery of enissomycin, a previously unreported antibacterial molecule. Enissomycin exhibited potent activity against Acinetobacter baumannii (MIC 4–8 μg/mL) and exhibited no significant cytotoxicity, highlighting its promise for drug development. Collectively, CI‐ARS 3 is a robust platform for the efficient dereplication of streptomycin and streptothricin, thereby expediting the discovery of novel antimicrobial compounds from Streptomyces .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StreptomycesAminoglycosidesGene SilencingAnti-Bacterial AgentsAcinetobacter baumanniiMicrobial Sensitivity TestsMultigene FamilyDrug DiscoveryBiosynthetic Pathways

Substanzen

AminoglycosidesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Microbiology and Synthetic Biology, College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province, People's Republic of China.
  • Department of Pharmaceutical Analysis and Metabolomics, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu Province, People's Republic of China.
  • Department of Pharmacy, Jiangbei Campus of The First Affiliated Hospital of Army Medical University, Chongqing, People's Republic of China.
  • Laboratory of Chemical Biology, College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province, People's Republic of China.
  • Department of Analytical Chemistry, China Pharmaceutical University, Nanjing, Jiangsu Province, People's Republic of China.

ORCID-Profile: Deli Xiao, Xuri Wu

Förderung

  • Anti-Infective Drug Research and Development Project at China Pharmaceutical University
  • Key Research and Development Project of Guangdong Province
  • National College Students Innovation and Entrepreneurship Training Program
  • National Natural Science Foundation of China

Zitieren

APA

Xu, Y., Du, Y., Yu, J., Zhao, Y., Li, Z., Wang, J., Chen, Y., Xiao, D., & Wu, X. (2026). Dual Silencing of Aminoglycoside Biosynthesis for the Discovery of Novel Antimicrobials in Streptomyces. Microbial Biotechnology, 19(7). https://doi.org/10.1111/1751-7915.70407

Vancouver

Xu Y, Du Y, Yu J, Zhao Y, Li Z, Wang J, et al. Dual Silencing of Aminoglycoside Biosynthesis for the Discovery of Novel Antimicrobials in Streptomyces. Microbial Biotechnology. 2026;19(7). doi:10.1111/1751-7915.70407

BibTeX
@article{Xu2026,
  author = {Xu, Yuncong and Du, Yali and Yu, Jiarong and Zhao, Yinghui and Li, Zhenlin and Wang, Jufen and Chen, Yijun and Xiao, Deli and Wu, Xuri},
  title = {Dual Silencing of Aminoglycoside Biosynthesis for the Discovery of Novel Antimicrobials in Streptomyces},
  journal = {Microbial Biotechnology},
  year = {2026},
  volume = {19},
  number = {7},
  doi = {10.1111/1751-7915.70407}
}
Kostenlos starten →